This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
IDEXX Laboratories Stock Climbs 39.4% in a Year: What's Driving It?
by Zacks Equity Research
IDXX shares jump 39% in a year, as CAG Diagnostics' recurring revenues, diagnostic innovations and software growth fuel momentum.
ISRGPositive Net Change EWPositive Net Change IDXXPositive Net Change GMEDPositive Net Change
medical medical-devices
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment
by Zacks Equity Research
NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.
ISRGPositive Net Change CAHPositive Net Change PAHCPositive Net Change NVCRNegative Net Change
medical medical-devices
After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ORICNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Is the Options Market Predicting a Spike in Spok Holdings Stock?
by Zacks Equity Research
Investors need to pay close attention to SPOK stock based on the movements in the options market lately.
SPOKNegative Net Change
medical medical-devices
Here's Why You Should Add DaVita Stock to Your Portfolio for Now
by Zacks Equity Research
DVA is gaining attention after strong Q4 results and steady global expansion, though its heavy reliance on commercial insurers remains a concern.
ISRGPositive Net Change DVAPositive Net Change CAHPositive Net Change PAHCPositive Net Change
medical medical-devices
BDX Secures CE Mark for Revello Stent to Treat Iliac Artery Disease
by Zacks Equity Research
BD wins CE Mark for its Revello vascular covered stent for iliac artery disease, expanding its peripheral vascular portfolio in the growing PAD treatment market.
BDXNegative Net Change ISRGPositive Net Change CAHPositive Net Change PAHCPositive Net Change
medical medical-devices
After Golden Cross, Iron Mountain (IRM)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IRMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hologic's Diagnostics Strength in Focus: Is More Upside Ahead?
by Moumi Mondal
HOLX's Diagnostics unit faces COVID-19 test declines, but Panther Fusion expansion, new assays and AI-driven Genius system support long-term growth potential.
ABTPositive Net Change BDXNegative Net Change HOLXNegative Net Change
medical medical-devices
Is This the Right Time to Retain IDXX Stock in Your Portfolio?
by Zacks Equity Research
IDEXX rides on strong CAG diagnostics growth, innovations and cloud software momentum, but solvency concerns and macro pressures cloud the outlook.
ALGNPositive Net Change IDXXPositive Net Change PAHCPositive Net Change NVSTNegative Net Change
medical medical-devices
COO Declines Despite Q1 Earnings Beat and Raised FY26 Outlook
by Zacks Equity Research
Cooper Companies tops Q1 EPS estimates and lifts FY26 outlook as MyDay and MiSight drive growth. Shares slip despite solid margin expansion.
EWPositive Net Change COONegative Net Change GMEDPositive Net Change PACBPositive Net Change
earnings medical medical-devices